Has Charisse Ward, MD received payments from drug or device companies?

Yes. Drug and device makers reported $8,893 in general payments to Charisse Ward, MD across 59 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Charisse Ward, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Charisse Ward, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Charisse Ward, MD

Interventional Cardiology · Slidell, LANPI 1528243300

Payments from drug & device makers

$8,893in general payments, 2019–2025

Across 59 payments — averaging $150.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Bard Peripheral Vascular, Inc.$5K
Medtronic$3K
Boston Scientific$449
Veryan Medical Incorporated$139
Edwards Lifesciences$133
Abbott$92
plus $510 from 17 others

What the payments were for

Consulting fees$4,50051%
Travel & lodging$2,72331%
Food & beverage$1,67019%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Bard Peripheral Vascular, Inc.	2	$4,638
Medtronic(2 entities)	12	$2,932
Boston Scientific	14	$449
Veryan Medical Incorporated	1	$139
Edwards Lifesciences	2	$133
Abbott	4	$92
Philips North America LLC	1	$89
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	4	$68
Actelion Pharmaceuticals US, Inc.	3	$60
Amgen	2	$43
Scpharmaceuticals Inc.	1	$26
Amarin Pharma, Inc.	2	$26
Regeneron Healthcare Solutions, Inc.	1	$24
Shockwave Medical, Inc	1	$22
Baxter Healthcare	1	$20
Bayer	1	$19
Esperion Therapeutics, Inc.	1	$19
Novartis	1	$18
Gilead	1	$18
Johnson & Johnson	1	$16
Silk Road Medical, Inc.	1	$16
Novo Nordisk	1	$15
Smith+Nephew	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LUTONIX$4,500
ADVISA DR MRI SURESCAN$2,666
BioMimics 3D Vascular Stent System$139
CoreValve Evolut$136
Watchman$111
Edwards SAPIEN 3 Transcatheter Heart Valve$108

How this compares

$8,893 in reported general payments places this provider in the 40th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana →

Medicare billing

Part B allowed, 2024

$71,681

Medicare patients

294

Services billed

614

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Metoprolol Succinate	14	$138
Carvedilol	21	$109
ClopidogrelClopidogrel Bisulfate	11	$23

Paid to pharmacies, not to this prescriber.